MAPT and Alzheimer disease: Due to its sensitivity, BrainAGE has outperformed biomarkers based on cerebrospinal fluid (e.g., Amyloid beta (Aβ42) total and phosphorylated tau) and has shown its ability to predict aberrant progression from Mild Cognitive Impairment to Alzheimer’s Disease (AD) (Gaser et al. 2013).